Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.

ASCO GI

ctDNA evaluation may play a prognostic role in stage III colon cancer treated...

Dr Jonathan Andrew Nowak - Dana-Farber Cancer Institute, Boston, USA

ctDNA evaluation may play a prognostic role in stage III colon cancer treated with celecoxib ( Dr Jonathan Andrew Nowak - Dana-Farber Cancer Institute, Boston, USA )

Addition of trastuzumab to chemo does not provide significant survival benefit...

Dr Anna Dorothea Wagner - Lausanne University Hospital, Lausanne, Switzerland

Addition of trastuzumab to chemo does not provide significant survival benefit in HER-2 positive stomach cancer ( Dr Anna Dorothea Wagner - Lausanne University Hospital, Lausanne, Switzerland )

Low-dose aspirin can reduce recurrence rates in colorectal cancer patients with...

Prof Anna Martling - Karolinska Institutet, Stockholm, Sweden

Low-dose aspirin can reduce recurrence rates in colorectal cancer patients with PI3K pathway alterations ( Prof Anna Martling - Karolinska Institutet, Stockholm, Sweden )

Nivolumab plus ipilimumab shows superior efficacy in metastatic colorectal...

Dr Thierry Andre - Sorbonne Université and Saint Antoine Hospital, Paris, France

Nivolumab plus ipilimumab shows superior efficacy in metastatic colorectal compared to nivolumab monotherapy ( Dr Thierry Andre - Sorbonne Université and Saint Antoine Hospital, Paris, France )

Blood-based test may provide a convenient and effective option for CRC...

Dr Aasma Shaukat - NYU Grossman School of Medicine, New York, USA

Blood-based test may provide a convenient and effective option for CRC screening in the average-risk U.S. population ( Dr Aasma Shaukat - NYU Grossman School of Medicine, New York, USA )

Everolimus plus lanreotide might be a new standard treatment in the first-line...

Dr Susumu Hijioka - National Cancer Center Hospital, Chuo City, Japan

Everolimus plus lanreotide might be a new standard treatment in the first-line setting for grade 1/2 GEP-NETs ( Dr Susumu Hijioka - National Cancer Center Hospital, Chuo City, Japan )

More from ecancer